Dianthus (Nasdaq: DNTH) raises $719M, ends Q1 2026 with $1.2B cash
Rhea-AI Filing Summary
Dianthus Therapeutics reported a Q1 2026 net loss of $40.8 million, or $0.85 per share, as it increased investment in its autoimmune disease pipeline. License revenue was $0.5 million, while higher research and administrative costs continued to drive operating losses.
The company ended the quarter with approximately $1.2 billion in cash, cash equivalents and investments, supported by an upsized underwritten offering that generated about $719 million in gross proceeds, which it expects to fund operations into 2030. Management highlighted an early GO decision in the CAPTIVATE CIDP trial, Orphan Drug Designation for claseprubart in Myasthenia Gravis, and progress on the gMG Phase 3 program, the MMN Phase 2 trial, and the DNTH212 Phase 1 study and planned rheumatology indications.
Positive
- Strengthened balance sheet and long runway: Approximately $719 million in gross proceeds from an upsized underwritten public offering lifted cash, cash equivalents and investments to about $1.2 billion as of March 31, 2026, which the company projects will fund operations into 2030.
- Pipeline and regulatory progress: An early GO decision in the CAPTIVATE CIDP trial, Orphan Drug Designation for claseprubart in Myasthenia Gravis, and clear FDA feedback on claseprubart trials support advancement of multiple neuromuscular programs.
- Broad development roadmap: The company outlined a Phase 3 EMERGE trial in gMG targeting mid‑2026 initiation, MoMeNtum Phase 2 top-line data in Q4 2026, and DNTH212 Phase 1 results in 2H 2026, providing several clinical catalysts.
Negative
- None.
Insights
Large cash raise and advancing trials strengthen Dianthus’s development position despite ongoing losses.
Dianthus ended Q1 2026 with about $1.2 billion in cash, cash equivalents and investments, helped by an upsized underwritten offering that brought in roughly $719 million in gross proceeds. This supports multiple late‑stage and early‑stage programs across neuromuscular and rheumatologic diseases.
Quarterly research and development expenses rose to $34.5 million and general and administrative costs to $12.5 million, contributing to a net loss of $40.8 million. These higher expenses reflect expanded clinical activity, including the CAPTIVATE CIDP program and preparation for the EMERGE Phase 3 trial in generalized Myasthenia Gravis.
Key upcoming milestones disclosed include CAPTIVATE Part B guidance by YE 2026, MoMeNtum Phase 2 top-line data in Q4 2026, DNTH212 Phase 1 healthy volunteer data in the second half of 2026, and EMERGE Phase 3 readout in the second half of 2028. The Orphan Drug Designation for claseprubart in Myasthenia Gravis and FDA feedback simplifying trial eligibility and monitoring may support execution of these studies.
8-K Event Classification
Key Figures
Key Terms
Orphan Drug Designation regulatory
Chronic Inflammatory Demyelinating Polyneuropathy medical
bifunctional fusion protein medical
drug-induced lupus medical
Type 1 interferon medical
complement pathway medical
Earnings Snapshot
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 5, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press release, dated May 5, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
DIANTHUS THERAPEUTICS, INC. |
|
|
|
|
Date: |
May 5, 2026 |
By: |
/s/ Adam M. Veness, Esq. |
|
|
|
Adam M. Veness, Esq. |
Exhibit 99.1
DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
AND REPORTS Q1 2026 FINANCIAL RESULTS
Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A
Claseprubart granted Orphan Drug Designation by FDA for Myasthenia Gravis
Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis (gMG) on track to initiate in mid-2026; top-line results anticipated in 2H’28
Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing; top-line results on track for Q4’26
Phase 1 healthy volunteer data for DNTH212 anticipated in 2H’26
Building a rheumatology franchise around DNTH212 with first three priority indications of Sjögren’s Disease (SjD), Systemic Lupus Erythematosus (SLE), and Dermatomyositis (DM)
Further strengthened the balance sheet with approximately $719 million in gross proceeds from an underwritten public offering of common stock and pre-funded warrants
Approximately $1.2 billion of cash as of March 31, 2026 provides expected runway into 2030
New York City and Waltham, Mass., May 5, 2026 – Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today reported financial results for the first quarter ending March 31, 2026, and provided an update on other recent business achievements.
“Q1 of this year was a pivotal period for Dianthus as we were able to make an early GO decision in PART A of the claseprubart CIDP CAPTIVATE study. In CAPTIVATE, we targeted 40 patients completing Part A and a response rate of approximately 50% based on precedent set with aC1s inhibition. We were able to make an early GO decision after 20 confirmed responders were identified with less than the 40 planned participants completing Part A. Claseprubart potency and early efficacy and safety results in CAPTIVATE Part A further build our confidence in claseprubart as a potentially best-in-disease therapy for neuromuscular diseases,” said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. “We are also excited to announce the first three priority indications selected for DNTH212, our first-in-class bifunctional fusion protein and next potential best-in-disease pipeline therapeutic: Sjögren’s Disease, Systemic Lupus Erythematosus, and Dermatomyositis. These are areas of high unmet need, where compelling biological rationale and clinical data support the complementary potential of targeting both BDCA2 and BAFF/APRIL to drive differentiated efficacy compared to single-mechanism approaches. Together, these indications represent a strong foundation for establishing a synergistic
1
www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036
rheumatology franchise around DNTH212, alongside the synergistic neuromuscular franchise we are building with claseprubart in gMG, CIDP and MMN.”
Claseprubart (DNTH103) Clinical Development
Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is designed to enable a more convenient, subcutaneous (S.C.), self-administered injection dosed as infrequently as once every two or four weeks. Claseprubart has the potential to be a best-in-disease pipeline-in-a-product across a range of autoimmune disorders with high unmet need.
Generalized Myasthenia Gravis (gMG)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multifocal Motor Neuropathy (MMN)
All Programs
In March 2026, the Company filed an 8K indicating receipt of written feedback from FDA agreeing to three proposals for all ongoing and planned future claseprubart trials:
2
www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036
Of note, there have been no cases of either SLE or DIL to date in any claseprubart program.
DNTH212 Clinical Development
DNTH212 is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems via two clinically validated pathways that are known drivers of autoimmune disease pathogenesis, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes.
Corporate Updates:
On March 12, Dianthus announced the closing of an upsized underwritten public offering of common stock and pre-funded warrants, with aggregate gross proceeds of approximately $719 million.
First-Quarter 2026 Financial Results
3
www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036
About Claseprubart (DNTH103)
Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, infrequently dosed, self-administered injection. Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways. As the classical pathway plays a significant role in disease pathology, claseprubart has the potential to be a best-in-disease pipeline-in-a-product across a range of autoimmune disorders with high unmet need. Dianthus is building a neuromuscular franchise with claseprubart and expects to initiate a Phase 3 trial in generalized Myasthenia Gravis in mid-2026, with top-line results expected in 2H’28, report top-line data from the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy in Q4’26, and provide an update on timing of top-line data from Part B of the Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy by YE’26.
Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.
About DNTH212
DNTH212 is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems via two clinically validated pathways that are known drivers of autoimmune disease pathogenesis, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes. Dianthus is building a rheumatology franchise with DNTH212 and has selected Sjögren’s Disease (SjD), Systemic Lupus Erythematosus (SLE), and Dermatomyositis (DM) as the first three prioritized indications for clinical development. A two-part Phase 1 study in China in healthy volunteers (Part A) and patients with systemic lupus erythematosus (Part B) is ongoing, with top-line results in healthy volunteers expected in 2H’26.
DNTH212 is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding future plans and prospects, including statements regarding the expectations or plans for discovery, preclinical studies, clinical trials and research and development programs, in particular with respect to claseprubart and DNTH212, and any developments or results in connection therewith, including the target product profile and administration of claseprubart and DNTH212; the anticipated timing of the initiation and results from those studies and trials; expectations regarding the clinical trial designs or indications; expectations
4
www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036
regarding the time period over which the Company’s capital resources are expected to be sufficient to fund its anticipated operations; and expectations regarding market size, patient population size, and potential opportunities for complement therapies, in particular with respect to claseprubart and DNTH212. Claseprubart and DNTH212 are investigational agents that are not approved as therapies in any indication in any jurisdiction worldwide. The words “opportunity,” “potential,” “milestones,” “runway,” “will,” “anticipate,” “achieve,” “near-term,” “catalysts,” “pursue,” “pipeline,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions (including the negatives of these terms or variations of them) generally identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.
Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of claseprubart and DNTH212 and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the preliminary interim analysis based on a limited number of patients from the Part A open label portion of the claseprubart CAPTIVATE study in patients with CIDP may not be predictive of the results or success of the remaining patients treated in Part A or patients treated in Part B of the CAPTIVATE study, that the development of claseprubart or DNTH212 may take longer and/or cost more than planned, that the Company or its partner may be unable to successfully complete the clinical development of the Company’s compounds, that the Company or its partner may be delayed in initiating, enrolling or completing its planned clinical trials, and that the Company's compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading "Risk Factors" included in the Company’s Annual Report on Form 10-K for the period ended December 31, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.
The forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Dianthus undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
5
www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036
DIANTHUS THERAPEUTICS, INC.
Consolidated Balance Sheets
(unaudited, in thousands)
|
|
March 31, |
|
|
December 31, |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
627,667 |
|
|
$ |
51,087 |
|
Short-term investments |
|
|
483,592 |
|
|
|
353,208 |
|
Accounts receivable, net |
|
|
1,230 |
|
|
|
52 |
|
Prepaid expenses and other current assets |
|
|
7,422 |
|
|
|
5,091 |
|
Total current assets |
|
|
1,119,911 |
|
|
|
409,438 |
|
Long-term investments |
|
|
113,868 |
|
|
|
110,135 |
|
Property and equipment, net |
|
|
274 |
|
|
|
296 |
|
Right-of-use operating lease assets |
|
|
1,293 |
|
|
|
1,337 |
|
Other assets and restricted cash |
|
|
11,538 |
|
|
|
9,716 |
|
Total assets |
|
$ |
1,246,884 |
|
|
$ |
530,922 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
5,274 |
|
|
$ |
9,725 |
|
Accrued expenses |
|
|
31,125 |
|
|
|
19,452 |
|
Current portion of deferred revenue |
|
|
1,485 |
|
|
|
1,188 |
|
Current portion of operating lease liabilities |
|
|
399 |
|
|
|
367 |
|
Total current liabilities |
|
|
38,283 |
|
|
|
30,732 |
|
Deferred revenue |
|
|
6,322 |
|
|
|
5,770 |
|
Long-term operating lease liabilities |
|
|
965 |
|
|
|
1,019 |
|
Total liabilities |
|
|
45,570 |
|
|
|
37,521 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders’ equity: |
|
|
|
|
|
|
||
Preferred stock |
|
|
— |
|
|
|
— |
|
Common stock |
|
|
54 |
|
|
|
43 |
|
Additional paid-in capital |
|
|
1,579,398 |
|
|
|
829,598 |
|
Accumulated deficit |
|
|
(377,563 |
) |
|
|
(336,729 |
) |
Accumulated other comprehensive (loss)/income |
|
|
(575 |
) |
|
|
489 |
|
Total stockholders’ equity |
|
|
1,201,314 |
|
|
|
493,401 |
|
Total liabilities and stockholders’ equity |
|
$ |
1,246,884 |
|
|
$ |
530,922 |
|
6
www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036
DIANTHUS THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
(unaudited)
|
|
Three Months Ended |
|
|
|||||
|
|
2026 |
|
|
2025 |
|
|
||
Revenues: |
|
|
|
|
|
|
|
||
License revenue |
|
$ |
463 |
|
|
$ |
1,163 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
||
Research and development |
|
|
34,528 |
|
|
|
27,003 |
|
|
General and administrative |
|
|
12,468 |
|
|
|
7,337 |
|
|
Total operating expenses |
|
|
46,996 |
|
|
|
34,340 |
|
|
Loss from operations |
|
|
(46,533 |
) |
|
|
(33,177 |
) |
|
Other income/(expense): |
|
|
|
|
|
|
|
||
Interest and investment income |
|
|
6,265 |
|
|
|
3,791 |
|
|
Loss on investment in former related party |
|
|
(302 |
) |
|
|
(5 |
) |
|
Loss on currency exchange, net |
|
|
(15 |
) |
|
|
(22 |
) |
|
Other expense |
|
|
(249 |
) |
|
|
(98 |
) |
|
Total other income |
|
|
5,699 |
|
|
|
3,666 |
|
|
Net loss |
|
$ |
(40,834 |
) |
|
$ |
(29,511 |
) |
|
Net loss per share attributable to common stockholders, |
|
$ |
(0.85 |
) |
|
$ |
(0.82 |
) |
|
Weighted-average number of shares of common stock outstanding |
|
|
48,032,742 |
|
|
|
35,790,700 |
|
|
Comprehensive loss: |
|
|
|
|
|
|
|
||
Net loss |
|
$ |
(40,834 |
) |
|
$ |
(29,511 |
) |
|
Other comprehensive (loss)/income: |
|
|
|
|
|
|
|
||
Unrealized (loss)/gain on marketable securities |
|
|
(1,064 |
) |
|
|
164 |
|
|
Total other comprehensive (loss)/income |
|
|
(1,064 |
) |
|
|
164 |
|
|
Total comprehensive loss |
|
$ |
(41,898 |
) |
|
$ |
(29,347 |
) |
|
7
www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036